The burden of progressive fibrotic interstitial lung disease across the UK.
Simpson, Thomas Barratt, Shaney L Beirne, Paul Chaudhuri, Nazia Crawshaw, Anjali Crowley, Louise E Fletcher, Sophie Gibbons, Michael A Hallchurch, Philippa Horgan, Laura
Simpson, Thomas
Barratt, Shaney L
Beirne, Paul
Chaudhuri, Nazia
Crawshaw, Anjali
Crowley, Louise E
Fletcher, Sophie
Gibbons, Michael A
Hallchurch, Philippa
Horgan, Laura
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2021-07-08
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Almost 15% of new referrals with non-IPF fibrotic ILD go on to develop a progressive fibrotic phenotype and would benefit from antifibrotic therapy https://bit.ly/3uPhClN
Citation
Simpson T, Barratt SL, Beirne P, Chaudhuri N, Crawshaw A, Crowley LE, Fletcher S, Gibbons MA, Hallchurch P, Horgan L, Jakaityte I, Lewis T, McLellan T, Myall KJ, Miller R, Smith DJF, Stanel S, Thillai M, Thompson F, Wallis T, Wu Z, Molyneaux PL, West AG. The burden of progressive fibrotic interstitial lung disease across the UK. Eur Respir J. 2021 Jul 8;58(1):2100221. doi: 10.1183/13993003.00221-2021
Type
Article